Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2641)	10/15/2009 2:43:52 PM
From: Jibacoa	Respond to of 3722

SLTM opened with a good UG today and is still up 17.86% with volume now of > 1,278,700 about 13x its ADV. bigcharts.marketwatch.com It announced today that it has received FDA clearance for the new Fraxel re:store Dual laser system. It takes the industry leading fractional laser technology to the next level by adding a novel 1927 nm wavelength, the first ever application of a Thulium laser in the aesthetics market. It is optimized for both on face and large body areas to address clearance of pigmentation and other superficial skin conditions all in a single treatment.<g> SLTM revenues were good on the first 2Qs, but the earnings on the 2ndQ were 52% lower.However, it is expected that the pending 2Qs results will show a better comparison on earnings. SLTM has been trading close to BV, it has NLTD and has a small +CF. In Dec2008 it acquired Reliant Technologies. It seems that with some further good news, the stock could make it to the $4 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2641)	2/11/2010 11:54:18 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

OPK was up 26.43% and is still up 18.975 at present.<g> Volume of > 1,300,000 is >5x its ADV. bigcharts.marketwatch.com It announced today the development of a simple diagnostic blood test for Alzheimer’s disease. The test, designed to detect elevated levels of antibodies unique to Alzheimer’s disease, was approximately 95% accurate in initial testing. The novel Alzheimer’s disease-specific antibodies were discovered using a proprietary platform being developed by OPKO that appears to be capable of identifying such biomarkers for any disease to which the immune system reacts, including cancer, autoimmune disease, neurodegenerative and infectious diseases. OPKO will perform additional studies required for regulatory approval and commercial use. The test could be useful in identifying patients for clinical trials for new Alzheimer’s drugs as well as to confirm the diagnosis in a clinical setting. Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, stated, “OPKO has begun to develop a range of new diagnostic tests for other neurological diseases, as well as cancers, starting with those for which early diagnosis is particularly important.” The stock traded above the resistane at $2 and the resistance to watch now is at $2.25 <g> bigcharts.marketwatch.com Bernard